REFRACTORY LEUKEMIA
Clinical trials for REFRACTORY LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY LEUKEMIA trials appear
Sign up with your email to follow new studies for REFRACTORY LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for stubborn leukemia: three-drug combo enters human trials
Disease control Recruiting nowThis study tests whether adding a new drug called roginolisib to two standard drugs (venetoclax and rituximab) is safe and works better for people with CLL that has come back or not responded to prior treatments. About 64 adults who have already tried at least two other therapies…
Matched conditions: REFRACTORY LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Jennifer R. Brown, MD, PhD • Aim: Disease control
Last updated May 26, 2026 06:08 UTC
-
New drug duo targets tough leukemias in early trial
Disease control Recruiting nowThis study tests whether combining two drugs, revumenib and mezigdomide, is safe for people whose acute leukemia has returned or not responded to prior treatment. It includes adults and teens aged 12+ with specific genetic subtypes (KMT2A-r, NUP98-r, or NPM1-m). The first part fi…
Matched conditions: REFRACTORY LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
New drug cocktail offers hope for tough leukemia cases
Disease control Recruiting nowThis study tests a combination of three drugs (venetoclax, chidamide, and azacitidine) in 30 adults whose acute myeloid leukemia has returned or not responded to standard treatment. The goal is to see if this mix can safely help more patients achieve remission. Participants must …
Matched conditions: REFRACTORY LEUKEMIA
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Xiamen University • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
New hope for hard-to-treat leukemia: early trial combines chemo with donor cells before transplant
Disease control Recruiting nowThis early-phase study is for people with relapsed or refractory leukemia, meaning their cancer has returned or not responded to standard treatments. The approach combines chemotherapy with an infusion of immune cells from a partially matched donor, given as a bridge to a stem ce…
Matched conditions: REFRACTORY LEUKEMIA
Phase: PHASE1 • Sponsor: Beijing 302 Hospital • Aim: Disease control
Last updated May 19, 2026 11:46 UTC